JP2008528542A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008528542A5 JP2008528542A5 JP2007552625A JP2007552625A JP2008528542A5 JP 2008528542 A5 JP2008528542 A5 JP 2008528542A5 JP 2007552625 A JP2007552625 A JP 2007552625A JP 2007552625 A JP2007552625 A JP 2007552625A JP 2008528542 A5 JP2008528542 A5 JP 2008528542A5
- Authority
- JP
- Japan
- Prior art keywords
- methylsulfonyl
- pyrimidin
- fluorophenyl
- isopropyl
- bis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 159000000007 calcium salts Chemical class 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 7
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 6
- 239000013078 crystal Substances 0.000 claims 5
- 239000000725 suspension Substances 0.000 claims 5
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- MMTXSCWTVRMIIY-PHDIDXHHSA-N (3r,5s)-3,5-dihydroxyhept-6-enoic acid Chemical compound OC(=O)C[C@H](O)C[C@H](O)C=C MMTXSCWTVRMIIY-PHDIDXHHSA-N 0.000 claims 3
- 229960004796 rosuvastatin calcium Drugs 0.000 claims 3
- 238000003756 stirring Methods 0.000 claims 3
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 claims 2
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 239000003945 anionic surfactant Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001207 fluorophenyl group Chemical group 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05100598 | 2005-01-31 | ||
| PCT/EP2006/050351 WO2006079611A1 (en) | 2005-01-31 | 2006-01-23 | Crystalline forms of rosuvastatin calcium salt |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008528542A JP2008528542A (ja) | 2008-07-31 |
| JP2008528542A5 true JP2008528542A5 (enExample) | 2009-03-26 |
Family
ID=36168368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007552625A Pending JP2008528542A (ja) | 2005-01-31 | 2006-01-23 | ロスバスタチンカルシウム塩の結晶形 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7932387B2 (enExample) |
| EP (1) | EP1844021A1 (enExample) |
| JP (1) | JP2008528542A (enExample) |
| CA (1) | CA2594692A1 (enExample) |
| WO (1) | WO2006079611A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
| GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
| CA2537271A1 (en) | 2003-08-28 | 2005-03-17 | Teva Pharmaceutical Industries, Ltd. | Process for preparation of rosuvastatin calcium |
| GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
| TW200526596A (en) | 2003-11-24 | 2005-08-16 | Teva Pharma | Crystalline ammonium salts of rosuvastatin |
| EP1689723B1 (en) | 2003-12-02 | 2011-04-27 | Teva Pharmaceutical Industries, Ltd. | Reference standard for characterization of rosuvastatin |
| TWI353981B (en) | 2005-02-22 | 2011-12-11 | Teva Pharma | Preparation of rosuvastatin |
| EP1805148A2 (en) | 2005-08-16 | 2007-07-11 | Teva Pharmaceutical Industries Ltd. | Crystalline rosuvastatin intermediate |
| WO2007125547A2 (en) | 2006-05-03 | 2007-11-08 | Manne Satyanarayana Reddy | Novel process for statins and its pharmaceutically acceptable salts thereof |
| EP1948618A1 (en) * | 2006-09-18 | 2008-07-30 | Teva Pharmaceutical Industries Ltd. | Crystalline rosuvastatin calcium |
| US8404841B2 (en) | 2006-10-09 | 2013-03-26 | Msn Laboratories Limited | Process for the preparation of statins and their pharmaceutically acceptable salts thereof |
| WO2009143776A1 (zh) | 2008-05-27 | 2009-12-03 | 常州制药厂有限公司 | 瑞舒伐他汀钙盐的制备方法及其中间体 |
| SI2373609T1 (sl) * | 2008-12-19 | 2013-12-31 | Krka, D.D., Novo Mesto | Uporaba amfifilnih spojin za kontrolirano kristalizacijo statinov in intermediatov statinov |
| EP2327682A1 (en) * | 2009-10-29 | 2011-06-01 | KRKA, D.D., Novo Mesto | Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates |
| SI2752407T1 (sl) * | 2009-01-14 | 2016-07-29 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Kristalni kalcijev rosuvastatin trihidrat |
| US8487105B2 (en) | 2009-01-19 | 2013-07-16 | Msn Laboratories Limited | Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof |
| HUP0900285A2 (en) | 2009-05-07 | 2011-01-28 | Egis Gyogyszergyar Nyilvanosan Mukoedoe Reszvenytarsasag | Rosuvastatin salts and preparation thereof |
| EP2464344A2 (en) * | 2009-08-13 | 2012-06-20 | Synthon B.V. | Pharmaceutical tablet comprising rosuvastatin calcium |
| WO2011074016A1 (en) * | 2009-12-17 | 2011-06-23 | Matrix Laboratories Ltd | Novel polymorphic forms of rosuvastatin calcium and process for preparation of the same |
| US8987444B2 (en) | 2010-01-18 | 2015-03-24 | Msn Laboratories Private Limited | Process for the preparation of amide intermediates and their use thereof |
| HU230737B1 (hu) | 2010-11-16 | 2018-01-29 | EGIS Gyógyszergyár Nyrt | Eljárás rosuvastatin só előállítására |
| CA2818007A1 (en) | 2010-11-22 | 2012-05-31 | Basf Se | Multicomponent system of rosuvastatin calcium salt and sorbitol |
| WO2012143308A1 (en) | 2011-04-18 | 2012-10-26 | Basf Se | Multicomponent crystalline system of rosuvastatin calcium salt and vanillin |
| WO2014050874A1 (ja) * | 2012-09-27 | 2014-04-03 | 東和薬品株式会社 | ロスバスタチンカルシウムの新規結晶形態およびその製造方法 |
| WO2017183040A1 (en) | 2016-04-18 | 2017-10-26 | Morepen Laboratories Limited | New polymorphic form of crystalline rosuvastatin calcium & novel processes for crystalline as well as amorphous rosuvastatin calcium |
| CN105837516B (zh) * | 2016-05-16 | 2018-07-10 | 山东新时代药业有限公司 | 一种瑞舒伐他汀钙晶型及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| GB9900339D0 (en) * | 1999-01-09 | 1999-02-24 | Zeneca Ltd | Chemical compounds |
| US6777552B2 (en) * | 2001-08-16 | 2004-08-17 | Teva Pharmaceutical Industries, Ltd. | Processes for preparing calcium salt forms of statins |
| GB0218781D0 (en) * | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
| EP1592668A1 (en) | 2003-02-12 | 2005-11-09 | Ciba SC Holding AG | Crystalline forms of pitavastatin calcium |
| WO2005037787A1 (en) | 2003-10-16 | 2005-04-28 | Ciba Specialty Chemicals Holding Inc. | Crystalline form of fluvastatin sodium |
| EP1709008A1 (en) * | 2004-01-19 | 2006-10-11 | Ranbaxy Laboratories Limited | Salts of hmg-coa reductase inhibitors and use thereof |
| US20070173536A1 (en) | 2004-02-06 | 2007-07-26 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of zolmitriptan |
| US20080234302A1 (en) | 2004-09-27 | 2008-09-25 | Mohammad Rafeeq | Novel Processes for Preparing Amorphous Rosuvastatin Calcium and a Novel Polymorphic Form of Rosuvastatin Sodium |
| EP1948618A1 (en) | 2006-09-18 | 2008-07-30 | Teva Pharmaceutical Industries Ltd. | Crystalline rosuvastatin calcium |
-
2006
- 2006-01-23 JP JP2007552625A patent/JP2008528542A/ja active Pending
- 2006-01-23 WO PCT/EP2006/050351 patent/WO2006079611A1/en not_active Ceased
- 2006-01-23 CA CA002594692A patent/CA2594692A1/en not_active Abandoned
- 2006-01-23 EP EP06707784A patent/EP1844021A1/en not_active Withdrawn
- 2006-01-23 US US11/883,008 patent/US7932387B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008528542A5 (enExample) | ||
| JP5697163B2 (ja) | 置換された３−ヒドロキシ−４−ピリドン誘導体 | |
| RU2006111354A (ru) | Кристаллическая форма кальциевой соли бис-[(e)-7-[4-(4-фторфенил)-6-изопропил-2-[метил(метилсульфонил]-пиримин-5-ил](3r, 5s)-3, 5-дигидроксигепт-6-еновой кислоты | |
| JP6008937B2 (ja) | １−（３−シアノ−１−イソプロピル−インドール−５−イル）ピラゾール−４−カルボン酸の結晶形とその製造方法 | |
| RU2001122164A (ru) | Кристаллическая кальциевая соль бис[(е)-7-[4-(4-фторфенил)-6-изопропил-2-[метил(метилсульфонил)амино]- пиримидин-5-ил]-(3r,5s)-3,5-дигидроксигепт-6-еновой кислоты] | |
| CN102197029B (zh) | 作为cdk抑制剂的亚砜亚胺取代的苯胺基嘧啶衍生物、其制备以及作为药物的用途 | |
| US20090036680A1 (en) | Salts of hmg-coa reductase inhibitors and use thereof | |
| JP2012532112A5 (enExample) | ||
| JP2003512467A (ja) | チアゾールおよびイミダゾ（４，５−ｂ）ピリジン化合物ならびにそれらの医薬用途 | |
| JP2015514060A5 (enExample) | ||
| JP2008528542A (ja) | ロスバスタチンカルシウム塩の結晶形 | |
| CN102282136A (zh) | 制备罗苏伐他汀的方法 | |
| EP1709008A1 (en) | Salts of hmg-coa reductase inhibitors and use thereof | |
| RU2019123404A (ru) | Производное пиримидина | |
| EP1797046A2 (en) | Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium | |
| TN2009000452A1 (en) | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof | |
| CN102471273B (zh) | 2-[[[2-[(羟基乙酰基)氨基]-4-吡啶基]甲基]硫代]-n-[4-(三氟甲氧基)苯基]-3-吡啶甲酰胺苯磺酸盐、其晶体、其多晶型物以及用于制备其的方法 | |
| JP2013541589A5 (enExample) | ||
| CN102807575B (zh) | 3-芳基-5-噻吩基-5H-噻唑并[3,2-a]嘧啶类衍生物及其应用 | |
| ES2342788T3 (es) | Proceso para la preparacion de rosuvastatina e intermedios. | |
| WO2008067440A2 (en) | Rosuvastatin dehydroabietylamine salt | |
| WO2005021511A1 (en) | A novel process for amorphous rosuvastatin calcium | |
| EP1879862B1 (en) | Magnesium salts of hmg-coa reductase inhibitors | |
| EP1737828A1 (en) | Amorphous magnesium salts of rosuvastatin | |
| NZ287550A (en) | 8-trifluoromethylquinolinecarboxylic acid derivatives; medicaments |